Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer

Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 1, 2013, Pages 113-125

  Leamon, Christopher P ^a   Lovejoy, Chandra D ^a   Nguyen, Binh ^a  

^a Endocyte Inc   (United States)

Author keywords

Biomarkers; Folate receptor; Patient selection; Platinum resistant ovarian cancer; Targeted therapy; VEGF

Indexed keywords

AFLIBERCEPT; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CA 125 ANTIGEN; CANFOSFAMIDE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EC 20; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE B; ETARFOLATIDE TC 99M; FARLETUZUMAB; FOLATE RECEPTOR; FOLIC ACID; GEMCITABINE; INIPARIB; IXABEPILONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VINTAFOLIDE;

ABDOMINAL PAIN; ALLERGIC REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; ASCITES; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER PROGNOSIS; CANCER SURVIVAL; DIGESTIVE SYSTEM PERFORATION; DNA REPAIR; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; LEUKOPENIA; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MYALGIA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PATIENT SELECTION; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84884803873     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S24943     Document Type: Review

References (84)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 [homepage on the Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. Accessed April 22, 2013.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397-1412.
4. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med. 1989;111(4):273-279.
5. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12(9):1748-1753.
6. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332(15):1004-1014.
7. Gynecologic Oncology Group, Markman M, Blessing J, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101(3):436-440.
8. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol. 2010;7(10):575-582.
9. Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single-agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41(5):418-424.
10. Eisenhauer EA, ten Bokkel Huinink WW, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654-2666.
11. Lortholary A, Largillier R, Weber B, et al; GINECO group France. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol. 2012;23(2):346-352.
12. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15(6):2183-2193.
13. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist. 2004;9(1):33-42.
14. Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase ll study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16(6):2233-2237.
15. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum-and paclitaxel-refractory ovarian cancer. Gynecol Oncol. 2000;79(1):116-119.
16. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15(3): 987-993.
17. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18(17):3093-3100.
18. Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for woman treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95(1):1-8.
19. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312-3322.
20. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19): 2811-2818.
21. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890-896.
22. Satyam A, Hocker MD, Kane-Maguire KA, Morgan AS, Villar HO, Lyttle MH. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. J Med Chem. 1996;39(8): 1736-1747.
23. Lyttle MH, Satyam A, Hocker MD, et al. Glutathione-S-transferase activates novel alkylating agents. J Med Chem. 1994;37(10):1501-1507.
24. Laborde E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ. 2010;17(9):1373-1380.
25. Vergote I, Finkler N, del Campo J, et al; ASSIST-1 Study Group. Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or-resistant ovarian cancer. Eur J Cancer. 2009;45:2324-2332.
26. Vergote I, Finkler NJ, Hall JB, et al. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2010;20(5): 772-780.
27. De Geest K, Blessing JA, Morris RT, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum-and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149-153.
28. Colombo N, Kutarska E, Dimopoulos M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012;30(31):3841-3847.
29. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171.
30. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol. 2012;30(Suppl 15):abstract LBA5002.
31. Coleman RL, Duska LR, Ramirez PT, et al. Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol. 2011;29(Suppl 15): Abstract 5017.
32. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15): 2512-2519.
33. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-379.
34. Birrer MJ, Konstantinopoulos P, Penson RT, et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol. 2011;29(Suppl): Abstract 5005.
35. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27(16):2686-2691.
36. Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer. 2009;45:1415-1423.
37. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol. 2013. In press.
38. Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res. 2008;14(23):7781-7789.
39. Heitz F, Harter P, Barinoff J, et al. Bevacizumab in the treatment of ovarian cancer. Adv Ther. 2012;29(9):723-735.
40. Burger RA, Brady MF, Bookman MA, et al; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483.
41. Perren TJ, Swart AM, Pfisterer J, et al; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26): 2484-2496.
42. Sharma T, Dhingra R, Singh S, et al. Aflibercept: A novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors. Mini Rev Med Chem. 2013;13(4):530-540.
43. Coleman RL, Duska LR, Ramirez PT, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011;12(12):1109-1117.
44. Tang PA, Cohen SJ, Kollmannsberger C, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res. 2012;18(21): 6023-6031.
45. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med. 2005;7(4):1-20.
46. Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol. 2012;24(5):564-571.
47. Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012;18(2):510-523.
48. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376.(9737):245-251.
49. Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet. Epub April 26, 2013.
50. Antony AC. The biological chemistry of folate receptors. Blood. 1992;79(11):2807-2820.
51. Zhao R, Goldman ID. The molecular identity and characterization of a Proton-coupled Folate Transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev. 2007;26(1):129-139.
52. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) in purine biosynthesis. Semin Oncol. 1999;26(2 Suppl 6):42-47.
53. Miotti S, Bagnoli M, Ottone F, Tomassetti A, Colnaghi MI, Canevari S. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem. 1997;65(4):479-491.
54. Tomao F, Panici PB, Frati L, Tomao S. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther. 2009;9(12):1727-1735.
55. Siu MK, Kong DS, Chan HY, et al. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PloS One. 2012;7(11):e47201.
56. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002;1(7):545-552.
57. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted neoplastic agent. Clin Cancer Res. 2004;10(12 Pt):4276s-4280s.
58. Zhao R, Diop-Bove N, Visentin M, Goldman ID. Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr. 2011;31:177-201.
59. Kamen BA, Smith AK. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol. 2012;70(1):113-120.
60. Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007;7:6.
61. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16(1):5288-5295.
62. Dosio F, Milla P, Cattel L. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs. 2010;11(12):1424-1433.
63. Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett. 2006;16(19):5093-5096.
64. Vlahov IR, Leamon CP. Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem. 2012;23(7): 1357-1369.
65. Leamon CP, Parker MA, Vlahov IR, et al. Synthesis and biological evaluation of EC20: a new folate-derived, (99 m)Tc-based radiopharmaceutical. Bioconjug Chem. 2002;13(6):1200-1210.
66. Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med. 2004;45(5):857-866.
67. Fisher RE, Siegel BA, Edell SL, et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med. 2008;49(6):899-906.
68. Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6(3):360-369.
69. Herceptin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf. Accessed April 22, 2013.
70. Zelboraf [prescribing information]. South San Francisco, CA: Genentech, Inc; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf. Accessed April 22, 2013.
71. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
72. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3(4):237-252.
73. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47054.
74. Gadducci A, Cosio S, Tana R, Genazanni AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol. 2009;69(1):12-27.
75. Verheijen RH, Cibula D, Zola P, et al; Council of the European Society of Gynaecologic Oncology. Cancer antigen 125: lost to follow-up?: a European society of gynaecological oncology consensus statement. Int J Gynecol Cancer. 2012;22(1):170-174.
76. Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512-517.
77. Madsen CV, Steffensen KD, Olsen DA, et al. Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. J Ovarian Res. 2012;5(1):23.
78. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicenter, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
79. Edelman MJ, Harb WA, Pal SE, et al. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012;7(10):1618-1621.
80. Kuo P, Naumann RW, Symanowski J, et al. 99 mTc-etarfolatide (EC20) SPECT imaging for the identification of ovarian and non-small cell lung cancer patients who are most likely to benefit from folate-receptor-targeted agent vintafolide (EC145). AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer and Biology Therapy; February 27-March 2, 2013; San Diego, CA, USA. abstract 41.
81. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74(2):193-198.
82. Fox JL. FDA moves on breakthrough therapies. Nat Biotechnol. 2013;31(5):374.
83. Leamon CP, Reddy JA, Wang Y, et al. EC0531: A potent folate-targeted tubulysin conjugate. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; April 17-21, 2010; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010; 70(Suppl 8):abstract nr 4414.
84. Reddy JA, Bloomfield A, Dorton R, et al. PSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; April 6-10, 2013; Washington, DC, USA. Philadelphia (PA): AACR; 2013.